If you have been reading about Gastric protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
== Classification == Hypermobility spectrum disorders are diagnosed when individuals have symptomatic joint hypermobility but do not meet the criteria for other connective tissue disorders, such as Ehlers–Danlos syndrome. In March 2017, the International Consortium on the Ehlers-Danlos Syndromes published a revised classification naming two syndromes: hypermobile EDS (hEDS), which has narrowly defined criteria, and hypermobility spectrum disorder (HSD) for those with some but not all the features of hEDS. This reclassification aimed to address the overlap between joint hypermobility syndrome and what was previously termed EDS-hypermobile type (EDS-HT). Patients who have a diagnosis of EDS-HT or JHS will fall into one of these two new categories. Hypermobility spectrum disorder does not include people with asymptomatic hypermobility or people with double-jointedness but no other symptoms. Hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders may be equally severe. HSD is further classified into different subtypes, which include:
Einsteinium is a synthetic, silvery, radioactive metal. In the periodic table, it is located to the right of the actinide californium, to the left of the actinide fermium and below the lanthanide holmium with which it shares many similarities in physical and chemical properties. Its density of 8.84 g/cm3 is lower than that of californium (15.1 g/cm3) and is nearly the same as that of holmium (8.79 g/cm3), despite einsteinium being much heavier per atom than holmium. Einsteinium's melting point (860 °C) is also relatively low—below californium (900 °C), fermium (1,527 °C) and holmium (1,461 °C). Einsteinium is a soft metal, with a bulk modulus of only 15 GPa, one of the lowest among non-alkali metals. Unlike the lighter actinides californium, berkelium, curium and americium, which crystallize in a double hexagonal structure at ambient conditions; einsteinium is believed to have a face-centered cubic (fcc) symmetry with the space group Fm3m and the lattice constant a = 575 pm. However, there is a report of room-temperature hexagonal einsteinium metal with a = 398 pm and c = 650 pm, which converted to the fcc phase upon heating to 300 °C. The self-damage induced by the radioactivity of einsteinium is so strong that it rapidly destroys the crystal lattice, and the energy release during this process, 1000 watts per gram of 253Es, induces a visible glow. These processes may contribute to the relatively low density and melting point of einsteinium.
AaH I is a hemorrhagic toxin which means it causes internal bleeding by damaging blood vessels. AaH I damages the walls of capillaries, causes them to leak blood internally, leading to death. Hemorrhagic toxins are common among other snake venoms as well like rattlesnakes and the western diamondback. There are four different types of AaH in Agkistrodon acutus venom, with AaH I being the strongest hemorrhagic one. Its proteolytic activity was sensitive to pH where it was 100 times stronger in weak alkaline conditions at pH 7.5. This is referring to the break down of proteins through the enzyme proteases. Aah I has three disulfide connections at Cys117-Cys197, Cys159-Cys181 and Cys157-Cys164. There is also one calcium ion, zinc ion, and three histidine zinc ligation in the structure. Each member of the metzincins has a zinc ion in its active site. Metzincins family is metalloproteinases that use a zinc ion in the enzymatic reaction. The zinc binding in AaH I is tetrahedral, three imidazole nitrogen atoms of histidine and one oxygen atom. It is unknown whether this oxygen atom is a water molecule or a hydroxide ion. A calcium ion occurs on the surface of the AaH I molecule opposite to the active-site cleft and close to the crossover point of the N-terminal and the C-terminal segment. Its position close to the C terminus, this calcium ion in the multi-domain parent structure could well play an important role in stabilizing and tightening the segment connecting the proteolytic domain with the succeeding disintegrin domain.
== Methods == Forensic chemists rely on a multitude of instruments to identify unknown substances found at a scene. Different methods can be used to determine the identity of the same substance, and it is up to the examiner to determine which method will produce the best results. Factors that forensic chemists might consider when performing an examination are the length of time a specific instrument will take to examine a substance and the destructive nature of that instrument. They prefer using nondestructive methods first, to preserve the evidence for further examination. Nondestructive techniques can also be used to narrow down the possibilities, making it more likely that the correct method will be used the first time when a destructive method is used.
Sources: en.wikipedia.org
=== Pharmacodynamics === Mestanolone is an AAS, with both androgenic and anabolic effects. It is very similar in its effects to androstanolone (dihydrotestosterone; DHT), and can be thought of as an orally active version of this AAS. Due to inactivation by 3α-hydroxysteroid dehydrogenase (3α-HSD) in skeletal muscle, mestanolone is described as a very poor anabolic agent, similarly to androstanolone and mesterolone. As mestanolone is 5α-reduced, it cannot be aromatized and hence has no propensity for estrogenic side effects such as gynecomastia. The drug also has no progestogenic activity. Like other 17α-alkylated AAS, mestanolone is hepatotoxic.
After the Chong Bok border clash that led to a Cambodian soldier's death on 28 May 2025, Paetongtarn immediately directed the Ministry of Foreign Affairs to de-escalate tensions through official channels, while firmly affirming Thailand's territorial claims. She assured the public that her government had maintained continuous consultation with the armed forces following the border incident. She emphasized Thailand's commitment to peace while affirming the country's readiness to defend its citizens. In a public statement, she said, "Thailand is a peaceful nation, but we are fully prepared to protect our people. While we prioritise peaceful solutions, our military is ready should clashes occur." She gave a speech in parliament declaring: "We will not give away even one square inch of land, but we will not go to war over misunderstandings either." She also visited the tense border area to offer support but publicly insisted on a peaceful resolution, a position that stood in contrast to the tougher rhetoric from some military figures. Behind the scenes, Paetongtarn engaged in personal, informal diplomacy, leveraging the long-standing relationship between her family and former Cambodian Prime Minister Hun Sen. Her goal was to use this personal connection to defuse the situation. This led to a private phone call between the two leaders on 15 June 2025.
== Interactions == Carbamazepine has a potential for drug interactions. Drugs that decrease breaking down of carbamazepine or otherwise increase its levels include erythromycin, cimetidine, propoxyphene, and calcium channel blockers. Grapefruit juice raises the bioavailability of carbamazepine by inhibiting the enzyme CYP3A4 in the gut wall and in the liver. Lower levels of carbamazepine are seen when administered with phenobarbital, phenytoin, or primidone, which can result in breakthrough seizure activity. Valproic acid and valnoctamide both inhibit microsomal epoxide hydrolase (mEH), the enzyme responsible for the breakdown of the active metabolite carbamazepine-10,11-epoxide into inactive metabolites. By inhibiting mEH, valproic acid and valnoctamide cause a build-up of the active metabolite, prolonging the effects of carbamazepine and delaying its excretion. Carbamazepine, as an inducer of cytochrome P450 enzymes, may increase clearance of many drugs, decreasing their concentration in the blood to subtherapeutic levels and reducing their desired effects. Drugs that are more rapidly metabolized with carbamazepine include warfarin, lamotrigine, phenytoin, theophylline, valproic acid, many benzodiazepines, and methadone. Carbamazepine also increases the metabolism of the hormones in birth control pills and can reduce their effectiveness, potentially leading to unexpected pregnancies.
Sources: en.wikipedia.org
A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Monoclonal antibodies are identical and can thus have monovalent affinity, binding only to a particular epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies are mixtures of antibodies derived from multiple plasma cell lineages which each bind to their particular target epitope. Artificial antibodies known as bispecific monoclonal antibodies can also be engineered which include two different antigen binding sites (FABs) on the same antibody. It is possible to produce monoclonal antibodies that specifically bind to almost any suitable substance; they can then serve to detect or purify it. This capability has become an investigative tool in biochemistry, molecular biology, and medicine. Monoclonal antibodies are used in the diagnosis of illnesses such as cancer and infections and are used therapeutically in the treatment of e.g. cancer and inflammatory diseases.
Pro-inflammatory myeloid cells along with production of the pro-inflammatory cytokines interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α) have been found to increase with age in rodents and humans. This is part of "inflammaging". Activation of these myeloid cells and consequent elevation in cytokine levels have been found to be suppressed by thymulin via inhibition of NF-κB signaling. Thymulin levels decrease with age.
=== Leg === Lower limb amputations can be divided into two broad categories: minor and major amputations. Minor amputations generally refer to the amputation of digits. Major amputations are commonly below-knee- or above-knee amputations. Common partial foot amputations include the Chopart, Lisfranc, and ray amputations. Common forms of ankle disarticulations include Pyrogoff, Boyd, and Syme amputations. A less common major amputation is the Van Nes rotation, or rotationplasty, i.e. the turning around and reattachment of the foot to allow the ankle joint to take over the function of the knee. Types of amputations include:
Swift's attempts to sell Chase's design to major railroads were rebuffed, as the companies feared that they would jeopardize their considerable investments in stock cars, animal pens, and feedlots if refrigerated meat transport gained wide acceptance. In response, Swift financed the initial production run on his own, then—when the American roads refused his business—he contracted with the GTR (a railroad that derived little income from transporting live cattle) to haul the cars into Michigan and then eastward through Canada. In 1880, the Peninsular Car Company (subsequently purchased by ACF) delivered the first of these units to Swift, and the Swift Refrigerator Line (SRL) was created. Within a year, the line's roster had risen to nearly 200 units, and Swift was transporting an average of 3,000 carcasses a week to Boston, Massachusetts. Competing firms such as Armour and Company quickly followed suit. By 1920, the SRL owned and operated 7,000 of the ice-cooled rail cars. The General American Transportation Corporation would assume ownership of the line in 1930.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.